Telfast-D

Quick links to important sections

Telfast-D

Method of action: Antitussive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telfast-D

Quick Facts

Property Description
Active ingredients Fexofenadine and Pseudoephedrine
Form Oral tablet, Extended-release tablet
Pharmacological class Antihistamine and Decongestant (Fixed-dose combination)
Common purpose Relief of symptoms of seasonal allergic rhinitis
Origin Synthetic

Telfast-D: What Type of Combination Medicine Is It?

Telfast-D is a fixed-dose combination (FDC) product structurally classified as a synthetic pharmaceutical agent that integrates two distinct active components into a single oral tablet preparation. The product is defined by its dual pharmacological class, functioning simultaneously as an Antihistamine and a Decongestant. This combination design provides a consolidated therapeutic approach, differentiating it from treatments that rely on only a single component.

It is frequently provided as an extended-release tablet, a pharmaceutical preparation designed for sustained action to support continuous symptom management, a characteristic clinically recognized for maintaining stable relief throughout the day.

What is the Composition of Telfast-D?

The composition of Telfast-D includes the active ingredients Fexofenadine hydrochloride and Pseudoephedrine hydrochloride. Fexofenadine is classified as a second-generation antihistamine, meaning it targets the allergic reaction by blocking histamine without the pronounced sedative effects associated with earlier medications. Fexofenadine is characterized by its ability to inhibit the effects of histamine with a low potential for sedating effects.

The second component, Pseudoephedrine, is classified as a sympathomimetic amine that acts as a nasal decongestant. The specific combination is available globally under various trade names, all sharing the core Fexofenadine-Pseudoephedrine formulation.

General Purpose of the Dual-Action Formulation

The general purpose of this dual formulation is to offer comprehensive relief from the concurrent symptoms of seasonal allergic rhinitis. The product is engineered to manage conditions where core allergic symptoms—such as itching, sneezing, and watery eyes—are accompanied by the physical discomfort of upper respiratory congestion and sinus pressure. This integrated strategy, which combines a non-sedating antihistamine with a decongestant, provides an efficient method for clearing blocked nasal passages while simultaneously inhibiting the underlying allergic cascade, a benefit that is widely supported by therapeutic consensus.

What side effects are possible with Telfast-D?

Possible Side Effects

As a combination of fexofenadine (an antihistamine) and pseudoephedrine (a decongestant), Telfast-D may cause various side effects. These can often be mild and temporary, but patients should be aware of all potential reactions.


Common Side Effects

The most commonly reported side effects typically affect the central nervous system or digestive system and include:

  • Headache
  • Insomnia (difficulty sleeping), due to the stimulant effect of pseudoephedrine
  • Nausea or stomach upset
  • Dry mouth
  • Dizziness or lightheadedness

Serious Side Effects

While rare, the pseudoephedrine component increases the risk of cardiovascular and central nervous system effects. Seek immediate medical attention if you experience:

  • Fast, pounding, or irregular heartbeat (palpitations, tachycardia)
  • Signs of an allergic reaction (e.g., swelling of the face, lips, tongue, or throat; difficulty breathing; rash, or hives)
  • Severe nervousness, anxiety, restlessness, or tremor
  • Difficulty urinating (urinary retention)
  • High blood pressure

Safety Information and Contraindications

Telfast-D should not be taken if you have taken a Monoamine Oxidase Inhibitor (MAOI) for depression or Parkinson's disease within the last 14 days. This combination can lead to a dangerous increase in blood pressure (hypertensive crisis).

Use with caution or avoid if you have pre-existing conditions such as severe coronary artery disease, very high blood pressure, glaucoma, an overactive thyroid gland (hyperthyroidism), or diabetes.

Avoid fruit juices (especially grapefruit, orange, or apple juice) and antacids containing aluminum or magnesium around the time of dosing, as they may reduce the absorption and effectiveness of fexofenadine.

Overdose and Emergency Response

The official regulatory documentation for the Fexofenadine/Pseudoephedrine combination product defines an overdose profile based on the toxicological risks of its two active components.

Overexposure to the fexofenadine component may result in documented clinical manifestations such as drowsiness, dizziness, and dry mouth. The most critical risks stem from the pseudoephedrine component (sympathomimetic toxicity), which affects the Central Nervous System and cardiovascular system.

Severe or life-threatening outcomes documented in the regulatory context include signs of extreme CNS stimulation, marked restlessness, tremors, and severe cardiac manifestations such as tachycardia (fast, irregular heartbeat), hypertension, convulsions, and potentially cardiovascular collapse.

In the event of an overdose or suspected overexposure, the official regulatory guidance mandates that individuals immediately seek emergency medical attention. Patients must call emergency services or contact a Poison Control Center right away, particularly if symptoms of severe CNS or cardiovascular distress occur. Management is classified as symptomatic and supportive treatment, as no specific antidote is known, and the regulatory information states that hemodialysis is ineffective for removing fexofenadine. Severe effects are documented as more likely to occur in adolescents and elderly patients.

Therapeutic Uses of Telfast-D

What Telfast-D Treats: Main Uses and Benefits

The medication is used to assist with relief across two primary domains of discomfort related to allergic responses and may be part of symptomatic management for adolescents and adults. This combination is commonly used to help with relief from symptoms associated with allergies.

Relief of Dual Allergic and Congestive Symptoms

This medication is generally applied in clinical settings that involve the concurrent presence of both core allergic inflammation and significant upper respiratory obstruction. It is used for managing symptoms associated with seasonal allergic rhinitis, helping to relieve primary allergic distress such as sneezing, runny nose, and itching of the eyes or nose, alongside the physical burden of a stuffy nose and painful sinus pressure. This combination helps manage symptoms that become more disruptive during flare-ups and create noticeable interference with daily stability.

“The formulation is relevant for conditions where symptoms may intensify temporarily, supporting the patient during difficult episodes by easing distress.”

Sustained Management of Distressing Manifestations

The formulation is relevant for conditions where symptoms may intensify temporarily, requiring sustained symptomatic assistance to cope with acute or recurrent episodes. It supports the handling of various distressing manifestations, including itchy eyes and watery eyes. The formulation supports general well-being during symptomatic phases and provides supportive relief that helps ease the overall symptom load during periods of peak allergen exposure.


Quick Fact: Primary Therapeutic Focus
Applied in situations involving seasonal allergic rhinitis where nasal congestion is a significant component.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Telfast-D?

The population eligibility for this medication is strictly defined by regulatory documents and largely relates to the Pseudoephedrine component. The official labeled use is restricted to adults and adolescents 12 years of age and older; its use is not established in children under 12 years.

Contraindicated Populations

Telfast-D is formally contraindicated (must not be used) in patients with specific severe conditions:

  • Severe hypertension (high blood pressure) or severe coronary artery disease.
  • Narrow-angle glaucoma or significant urinary retention.
  • Known hypersensitivity to Fexofenadine, Pseudoephedrine, or any component.
  • Patients currently taking or who have recently stopped (within 14 days) a Monoamine Oxidase Inhibitor (MAOI).

Use Restrictions and Cautions

  • Renal Function: Patients with decreased renal function are designated as requiring a restricted initial dose due to altered drug elimination.
  • Physiological Status: Use is generally not recommended for women who are breastfeeding because Pseudoephedrine is known to pass into breast milk.
  • Comorbidities: Caution is advised in patients with existing non-severe hypertension, diabetes mellitus, hyperthyroidism, or an enlarged prostate, as stated in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific combinations and substances that interact with Fexofenadine and Pseudoephedrine, the active ingredients in this combination medicine.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), or use within 14 days of stopping MAOI treatment, is a formal contraindication. This restriction is due to the Pseudoephedrine component. Combining the medicine with other sympathomimetics or adrenergic agents may result in additive pharmacodynamic effects and is generally restricted.

Pharmacokinetic and Timing-Based Interactions

Substances that modulate drug transporters, such as the antibiotics Erythromycin and the antifungal Ketoconazole, are documented to significantly increase the plasma concentration (AUC/Cmax) of Fexofenadine. Conversely, Antacids containing Aluminum and Magnesium Hydroxide substantially decrease Fexofenadine exposure and must not be taken closely in time; separation by at least two hours is required. Furthermore, the bioavailability of Fexofenadine is decreased when taken with fruit juices (e.g., apple, grapefruit, orange), which should therefore be avoided.

Population-Specific Notes

The risk of Pseudoephedrine accumulation is greater in patients with impaired renal function, as its clearance is reduced via the renal elimination pathway.

Mechanism of Action

This product's mechanism of action involves two distinct pharmacological pathways: H1 receptor blockade and alpha-adrenergic agonism.

H1 Receptor Blockade by Fexofenadine

The component fexofenadine functions as an antagonist, engaging and occupying peripheral histamine H1 receptors . By preventing the binding of the inflammatory mediator histamine, this mechanism reduces the level of histamine-mediated H1 receptor activation. This influences the resulting changes in capillary permeability and stimulation of sensory nerve endings.

Sympathetic Regulation of Nasal Vasculature by Pseudoephedrine

The second component, pseudoephedrine, acts as an agonist on alpha-adrenergic receptors located on the smooth muscle of blood vessels within the nasal mucosa. Activation of these receptors initiates a signaling sequence that induces vasoconstriction. This action decreases the volume of blood and interstitial fluid within the nasal mucosa, resulting in a reduction of tissue volume.

Dosage and Administration Information

How to Use Telfast-D: Official Administration Guidelines

Telfast-D, a fixed-dose combination product, is administered by the oral route as an extended-release tablet. The usage protocols are defined to ensure the medicine's standardized administration.


Administration Scope

Instruction Category Official Guideline
Route of administration Oral route only.
Dosing schedule 12-Hour Tablet (60 mg / 120 mg): One tablet. 24-Hour Tablet (180 mg / 240 mg): One tablet.
Timing in relation to meals Must be taken on an empty stomach (at least one hour before or two hours after food).
Age-group administration rules Approved for use in adults and children 12 years of age and older.

Procedural and Contextual Requirements

Instruction Category Official Guideline
Frequency and schedule The 60 mg / 120 mg tablet is taken twice daily (every 12 hours); the 180 mg / 240 mg tablet is taken once daily.
Preparation and conditions The tablet must be swallowed whole with a full glass of water; it must not be divided, crushed, or chewed.
Use-context constraints Avoid consumption with fruit juices (e.g., grapefruit, orange, apple) and separate administration from aluminum or magnesium-containing antacids by at least two hours.
Population-specific rules For patients with decreased renal function, the recommended starting dose for the 12-hour formulation is one tablet once daily (every 24 hours).

Connection to the overall use protocol (2–4 sentences):

These instructions establish a standardized approach to usage based on fixed dosing intervals and mandatory administration conditions. Adherence to these protocols, particularly taking the tablet on an empty stomach and avoiding fruit juices, is required to prevent interference with the drug's intended action and absorption. The dose adjustment for individuals with decreased renal function further defines the standardized treatment framework.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Telfast-D

Evidence for Relief of Seasonal Allergic Rhinitis with Nasal Congestion

The research examined conditions characterized by fluctuating or episodic manifestations of allergic rhinitis, particularly when that condition involves significant nasal congestion (stuffy nose or sinus pressure). Researchers explored this through highly structured Randomized, Controlled Trials (RCTs), as well as in specific Allergen Exposure Unit Studies. Research primarily examined endpoints related to physical discomfort, which included monitoring the key allergic symptoms (such as sneezing and itching) alongside patient-reported outcomes describing perceived discomfort related to nasal obstruction. Evidence describes patterns related to symptoms that occur during episodes where symptoms become more noticeable.

Design of the Key Clinical Trials

The research examined the dual formulation in studies where participants were randomly assigned to receive the combination product, an inactive placebo, or sometimes one of the two active ingredients alone. Studies used this design to observe patterns in patient reports compared to an environment with no active treatment. The studies primarily included adults and adolescents (age 12 and older) who were experiencing periods of heightened symptom activity related to seasonal allergens. The findings describe group patterns related only to the populations studied, as those with complex or serious concurrent health issues were often excluded.

Research on Duration and Follow-up Periods

The majority of the evidence comes from studies exploring short-term symptom patterns over defined time intervals. The standard controlled trials was observed in participants for periods up to 14 days (two weeks). Separate studies focusing on episodes where symptoms become more noticeable were conducted over a period of just a few hours to establish how quickly a pattern of change may be observed. While these shorter time intervals contribute to understanding episodic or acute symptom patterns, the follow-up durations were limited when considering the full length of a typical allergy season.

Key Studies & References

  1. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis
  2. Fexofenadine and Pseudoephedrine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Telfast-D (FAQ)

Q: How quickly should I expect Telfast-D to start working for my congestion and allergies?

A: Studies and official information indicate that the time to onset for symptom relief can be observed relatively quickly. Clinical study data suggests the onset of action for symptom relief can be observed as early as 60 minutes following administration.

Q: How long does the relief from a single dose of Telfast-D typically last?

A: The intended duration of relief is reflected in the product’s official administration schedule. This schedule is typically every 12 hours or every 24 hours, depending on the specific product formulation you are using.

Q: What are the most commonly reported side effects people mention for Telfast-D online?

A: Regulatory documents derived from clinical trials list the most frequently observed side effects. These commonly include headache, insomnia (difficulty sleeping), and nausea or an upset stomach.

Q: Can Telfast-D interact with antidepressant or anti-anxiety medications?

A: The product is formally contraindicated (must not be used) with Monoamine Oxidase Inhibitors (MAOIs), and combining it with other sympathomimetics is restricted due to the risk of additive effects. Patients should consult their healthcare provider about non-MAOI antidepressants or anti-anxiety medications, as the official product label only specifies the restrictions mentioned.

Q: Is Telfast-D generally safe for older adults to use?

A: Official labeling states that adults 65 years of age and older should consult a doctor or health professional before use. This caution is due to the potential for older patients to be more sensitive to the effects of the medication's active ingredients.

Q: Is it normal to feel a bit more energetic or jittery after taking Telfast-D?

A: Feelings of being energetic or jittery may occur. The pseudoephedrine component acts as a stimulant, and regulatory adverse reaction listings include feelings of nervousness, restlessness, and anxiety. This stimulant effect is also linked to the common side effect of insomnia.

Q: Why do some people say Telfast-D keeps them awake at night?

A: The official product information lists Insomnia (difficulty sleeping) as a common side effect of this medication. This is primarily attributed to the stimulant effect of the pseudoephedrine component, which can interfere with normal sleep patterns.

Q: Is there a generic version of the active ingredients in Telfast-D?

A: The active ingredients in Telfast-D, Fexofenadine and Pseudoephedrine, are available under various trade names and generic product labels that have been reviewed by regulatory bodies.

Q: Are there any specific foods or drinks that should be avoided when taking Telfast-D?

A: Official directions specify that the product should not be taken with fruit juices such as grapefruit, orange, or apple juice. Additionally, administration should be separated from antacids containing aluminum or magnesium by at least two hours.

Q: Does taking Telfast-D regularly cause a 'rebound' congestion when you stop?

A: Regulatory monographs indicate that oral pseudoephedrine, which is the decongestant in this product, produces little if any rebound congestion. This is a distinction from the effect commonly associated with certain topical nasal spray decongestants.

Q: Are there any known interactions between Telfast-D and common herbal supplements?

A: While specific herbal supplements may not be listed, official patient information advises checking with a healthcare provider before combining this medication with any other medicines, vitamins, or supplements.

Q: Do people typically find Telfast-D more effective for sinus pressure than regular Telfast?

A: Since the decongestant component is indicated for relieving sinus congestion and pressure, the combination product addresses congestion in addition to the core allergy symptoms. Regular Telfast (fexofenadine only) does not contain a decongestant.

Q: Is there any difference in effectiveness between brand-name Telfast-D and a generic equivalent?

A: According to regulatory standards for generic drugs, any generic version of this product must contain the same active ingredients and demonstrate that it is absorbed similarly. Generic versions are required to meet the same quality and performance standards as the brand-name product.

Q: Can Telfast-D be used to help with symptoms of the common cold?

A: While the primary approved use is for symptoms associated with seasonal allergic rhinitis, the decongestant component has an official indication for the temporary relief of congestion associated with the common cold.

Q: What should I do if I feel dizzy or lightheaded after taking Telfast-D?

A: If these or any severe reactions occur, official safety instructions state that patients should seek medical help right away or contact a Poison Control Center.

Q: Is Telfast-D recommended for people whose primary symptom is an itchy throat?

A: Yes, the antihistamine component is indicated to relieve various allergic symptoms, including itching of the nose, throat, or roof of the mouth.

Q: Can Telfast-D cause changes in sleep patterns?

A: The label lists insomnia (difficulty sleeping) as a common side effect of the medication. This is a known consequence of the stimulant action of the pseudoephedrine component, which can lead to changes in sleep patterns.

Q: Can Telfast-D be taken while someone is undergoing dental work or local anesthesia?

A: Regulatory information suggests that patients undergoing surgery or dental procedures should inform their doctor or dentist due to the presence of pseudoephedrine.

Q: What distinguishes the two active components in Telfast-D and their purpose?

A: Telfast-D is a combination medicine containing two distinct components. Fexofenadine is the antihistamine that targets the allergic reaction to relieve symptoms like sneezing and itching. Pseudoephedrine is the decongestant that relieves nasal and sinus congestion.

Q: Is the combination of fexofenadine and pseudoephedrine well-studied?

A: Official regulatory documents confirm that the combination has been thoroughly examined. It has been the subject of structured Randomized, Controlled Trials (RCTs) and specialized Allergen Exposure Unit Studies to establish its efficacy and safety profile.

Q: What is the main reason Telfast-D is often recommended over just taking a standalone decongestant?

A: The product is a fixed-dose combination designed to provide comprehensive relief. It treats both the underlying allergic symptoms (via the antihistamine) and the resulting nasal congestion and sinus pressure (via the decongestant) simultaneously.

Q: Are there known cases of Telfast-D causing changes in heart rate?

A: Official warnings and adverse reaction reports list fast, pounding, or irregular heartbeat (such as palpitations or tachycardia) as a serious potential side effect associated with the medication, particularly due to the decongestant component.

How should Telfast-D be stored and disposed of?

Storage and Disposal Requirements for Telfast-D

Official regulatory guidelines define strict conditions for the storage and disposal of Telfast-D tablets to ensure product stability and safety.

Storage Conditions

Requirement Description
Temperature Store at controlled room temperature, typically below 25 C or 30 C.
Protection Keep the medicine protected from moisture (avoid humid areas like bathrooms) and excessive heat.
Packaging Keep the tablets in the original blister pack and outer carton until use to maintain stability and prevent light exposure.
Child Safety Keep Telfast-D out of the sight and reach of children at all times.

Disposal Rules

Regulatory sources instruct that unused or expired Telfast-D must not be disposed of by flushing down a toilet or sink, nor should it be placed in household trash. To minimize environmental impact, the medicine should be returned to a pharmacy or an authorized community take-back program for proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Telfast-D found in:

A-Z Index: